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Pathogenesis of refractory secondary hyperparathyroidism. sensor receptor [8, 9]; also, the poor response to calcitriol
Calcitriol is currently used to reduce parathyroid hormone treatment is associated with factors such as the failure
(PTH) levels in uremic patients. However, a significant number to control the serum phosphorus [2, 10, 11]. This reviewof patients fail to respond to calcitriol therapy. The data suggest
will analyze the characteristics and factors involved inthat a poor response to calcitriol can be anticipated in patients
the pathogenesis of refractory hyperparathyroidism.with severe hyperparathyroidism (with a high basal PTH levels)
and uncontrolled serum phosphate. The abnormal parathyroid
response to calcitriol in uremic patients with severe parathyroid
hyperplasia may be attributed, to a large extent, to the develop- ABNORMAL PARATHYROID FUNCTION IN
ment of nodular hyperplasia as a result of clonal transformation REFRACTORY HYPERPARATHYROIDISM
from a diffuse polyclonal hyperplasia. The factors involved
In a recent study [12] we analyzed parathyroid func-in the development of polyclonal parathyroid hyperplasia, at
earlier stages of secondary hyperparathyroidism, appear to be tion (PTH-Ca curve) in 50 hemodialysis patients with
the same factors that stimulate PTH secretion and synthesis: PTH greater than 300 before and after 3 months of bolus
hypocalcemia, hyperphosphatemia and low serum calcitriol calcitriol therapy (3–6 g). Patients were divided intolevels. Studies performed in vitro using parathyroid tissue from
responders and non-responders based on whether theuremic patients who required parathyroidectomy demonstrate
predialysis PTH value decreased by 40% or more inthat in nodular hyperplasia there is an abnormal response to
calcium and calcitriol, which suggests that there are factors response to CTR treatment; this value was selected be-
intrinsic to the hyperplastic cell (such as decrease in calcium cause it represented the median for the total group of
sensor receptors and vitamin D receptors) responsible for an
50 patients. Before initiation of treatment, the meanabnormal regulation of parathyroid function. Accumulation of
basal PTH, maximal PTH, and minimal PTH werephosphate is a key factor in the pathogenesis of secondary
hyperparathyroidism and a poor response to calcitriol treat- greater in non-responders than responders. Serum cal-
ment is associated with the failure to control the serum phos- cium concentration was similar in both groups and the
phorus. High phosphate stimulates PTH secretion as demon- serum phosphate was greater in non-responders than
strated by in vivo and in vitro studies. In addition, animal
responders. The data suggest that a poor response tostudies strongly suggest that phosphate increases parathyroid
calcitriol can be anticipated in patients with severe hy-cell proliferation. There are growth-related genes potentially
involved in uremic hyperparathyroidism; however, changes in perparathyroidism and uncontrolled serum phosphate.
the expression of these genes may be the consequence rather The probability of a response to CTR based on pre-CTR
than the cause of parathyroid hyperplasia.
basal PTH values is shown for the model in Figure 1. A
50% probability of a response (40% reduction in basal
PTH) was observed at a pre-CTR basal PTH value of 750
Calcitriol is currently used to reduce parathyroid hor- pg/mL. At a basal PTH of 1200 pg/mL, the probability of
mone (PTH) levels in uremic patients [1], however, a a response to CTR was less than 20% and at a basal
significant number of patients fail to respond to calcitriol
PTH of 400 pg/mL, the probability of a response ap-
therapy [2–4]. These failures have been ascribed to in-
proached 80%.
trinsic factors associated with large, hyperplastic para-
One of the parameters analyzed in this study was thethyroid glands such as nodular hyperplasia [5–7] with
ratio of basal to maximal PTH (basal PTH divided bydecreased levels of vitamin D receptor [7] and calcium
the maximal PTH; this fraction was multiplied by 100),
which in normal volunteers is 20% to 25% [13]. By cor-
recting the actual PTH for the overall capacity to produceKey words: Uremia, calcitrol, parathyroid homone, nodular hyperpla-
sia, vitamin D receptor. PTH (maximal PTH), a measure of the relative degree
of PTH stimulation is obtained. When the basal calcium 2002 by the International Society of Nephrology
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be attributed, to a large extent, to the development of
nodular hyperplasia as a result of clonal transformation
from a diffuse hyperplasia [15, 16]. Different research
groups have reported that in nodular areas there is a
decrease in calcium sensor receptor expression [8, 9],
which may explain the abnormal response of these para-
thyroid glands to the increase in calcium induced by
calcitriol administration. Calcitriol acts on parathyroid
glands independently of calcium, however, the decrease
in vitamin D receptor density also observed in nodular
hyperplasia [7] may explain the refractoriness to calcit-
riol treatment. Studies performed in vitro using parathy-
Fig. 1. Logistic regression model to predict response to calcitriol treat- roid tissue from uremic patients that required parathy-
ment. Stepwise logistic regression analysis showed that the pre-calcitriol
roidectomy demonstrate that in nodular hyperplasiabasal PTH level was the most important predictor of the probability
of a 40% reduction in basal PTH during calcitriol treatment. Using the there is an abnormal response to calcium [17, 18] and
above model, a 50% probability of a response (40% reduction in basal calcitriol [19], which suggests that there are factors intrin-
PTH) was observed at a pre-calcitriol basal PTH value of 750 pg/mL.
sic to the cell (such as decrease in calcium sensor andAt a basal PTH of 1200 pg/mL, the probability of a response to calcitriol
was less than 20%, and at a basal PTH of 400 pg/mL, the probability vitamin D receptors) that are responsible for an abnor-
of a response approached 80%. mal regulation of parathyroid function. We have evalu-
ated the ability of calcium to reduce PTH secretion in
vitro in parathyroid tissue from uremic patients that re-
quired parathyroidectomy [18]. As shown in Figure 3,is low, the basal to maximal PTH ratio should be high,
the degree of inhibition of PTH secretion by calciumindicating that the parathyroid gland is using more of its
was greater in diffuse than nodular hyperplasia; in primaryoverall capacity to correct the low calcium; conversely,
parathyroid hyperplasia very high calcium concentrationsan increase of calcium must decrease basal PTH relative
were necessary to produce a significant decrease in PTHto maximal PTH. Figure 2 shows the changes in basal/
secretion. In a different study we evaluated in vitro, themaximal PTH ratio produced by calcitriol treatment in
effect of calcitriol on parathyroid cell cycle and apoptosisresponders and non-responders. The basal/maximal PTH
in parathyroid glands from patients with severe hyper-ratio, which reflects the relative degree of parathyroid
parathyroidism [19]. In these glands, parathyroid cell pro-gland sensitivity to the serum calcium, decreased in the
liferation was not inhibited by concentrations of calcitriolresponders group from 52 3% to 33 3% (P 0.001)
ranging from 1010 to 108 mol/L; a moderate decreaseafter CTR treatment as the serum calcium concentration
in proliferation was observed when calcitriol concentra-increased (Fig. 2A). Conversely, in the non-responders
tion in the medium reached 107 mol/L (Fig. 4). In thisgroup, the basal/maximal PTH ratio did not change de-
study, it was observed that a high concentration ofspite the increase in serum calcium and a similar shift
calcitriol produced a decrease in the number of apoptoticto the right of the PTH-calcium curve (Fig. 2B). The
cells that was parallel to the decrease in proliferation.
magnitude of the absolute reduction in PTH in the re-
Because calcitriol simultaneously inhibits cell prolifera-
sponder group (Fig. 2C) and the lack of a change in the
tion and apoptosis, a reduction in the parathyroid gland
non responder group (Fig. 2D) can be appreciated in
mass may not occur as a direct effect of calcitriol treat-
the PTH-calcium curves shown in these figures.
ment.
The PTH response to calcitriol was also affected by
high serum phosphate. In both groups, responders and
NODULAR HYPERPLASIAnon responders, patients with serum phosphate greater
than 6 mg/dL showed less reduction in PTH than those The reason for the high frequency of clonal prolifera-
with serum phosphate below 6 mg/dL. tion is unclear. Probably the long-standing stimulation
The set point was not different in responders and non of a tissue with a usually extremely slow growth pattern
responders. As reported in a previous work [14], we have favors clonal transformation; defects in DNA repair
observed that among patients with advanced hyperpara- mechanisms may play a role [20]. Mendes et al [5] first
thyroidism, a high set point is only observed in patients described frequent nodular formations in parathyroid
with high PTH and elevated serum calcium, which sug- glands from uremic patients with severe secondary hy-
gests that the PTH is driving the serum calcium; these perparathyroidism. Nodular formation was observed in
patients are not likely to respond to calcitriol therapy. 50% of glands weighing between 0.25 and 0.5 g parathy-
The abnormal parathyroid response to calcitriol in roid and in more than 90% of glands weighing more than
0.5 g [21]. Nodules are formed by a greater proportion ofuremic patients with severe parathyroid hyperplasia may
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Fig. 2. Patterns of PTH secretion in respond-
ers and non-responders. The mean basal/max-
imal PTH ratio (100) is shown before (solid
line) and after (dashed line) calcitriol treat-
ment in A and B and the absolute changes in
basal and maximal PTH are shown in C and
D. Before calcitriol treatment, the mean basal/
maximal PTH ratio was similar in the Re-
sponders (A) and Non-Responders (B). In both
groups, a similar shift to the right of the PTH-
calcium curve was observed during calcitriol
treatment with sustained increases in the se-
rum calcium concentration. However, only in
the Responders was the rightward shift in the
PTH-calcium curve associated with a decrease
in the mean basal/maximal PTH ratio. In C
and D, the absolute values for basal, maximal,
and minimal PTH are shown. Before calcitriol
treatment, the basal and maximal PTH levels
were less in the Responders (C) than the Non-
Responders (D), and minimal PTH was not
different. With calcitriol treatment basal, max-
imal, and minimal PTH values decreased in
the Responders (C), but were essentially un-
changed in the Non-Responders (D).
actively replicating cells [22–25]. Nodular hyperplasia gene, have been found in only 10% of the patients [31, 32]
and allelic loss of the Ha-ras gene and the tumor suppres-was also associated with a greater resistance to medical
suppression of PTH oversecretion [24, 25], and recur- sor gene WT1 in approximately 10% of the patients [33].
The expression of calcium sensor receptor and vitamin Drence rates of hyperparathyroidism after PTX were sig-
nificantly higher when nodular tissue instead of purely receptor are decreased in nodular hyperplasia, however,
mutations of these two important receptors have nothyperplastic tissue was autografted [26].
been identified [29].Several authors have shown, using X chromosome in-
activation analysis, that benign monoclonal tumors are
present in a large proportion of hyperplastic glands
DIFFUSE HYPERPLASIA[27–29] and there was no correlation between clonal
development and morphology [27]. Clonal development The nodular hyperplasia of the parathyroids occurs at
may be caused by mutations or losses of tumor suppres- a late stage in the evolution of secondary hyperparathy-
sor genes or activation of tumor enhancer genes [29, 30]. roidism. During earlier stages of secondary hyperpara-
thyroidism, parathyroid growth is polyclonal. The factorsLosses on chromosome 11, the location of the menin
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ism [39, 40], other authors have not observed such asso-
ciation [41–43].
Accumulation of phosphate is a key factor in the patho-
genesis of hyperparathyroidism secondary to renal fail-
ure. High phosphate stimulates PTH secretion as demon-
strated by in vivo and in vitro studies [44–47]. In addition,
animal studies strongly suggest that phosphate increases
parathyroid cell proliferation [34, 48–50], however, possi-
ble mechanisms are not clear. In a recent work, Brown
et al [51] clearly demonstrated that in renal failure rats
fed a high phosphorus diet, the resulting parathyroid
hyperplasia was associated with a decrease in calcium
sensing receptor (CaR). This decrease in calcium sensing
receptor may have been a direct effect of phosphate or
a consequence of parathyroid gland hyperplasia. In a
Fig. 3. Parathyroid function in adenomas, nodular and diffuse hyper- more recent study the same group shows that decreaseplasia. The inhibition of PTH secretion by calcium in vitro in human
in CaR precedes development of hyperplasia [52]. In aparathyroid adenoma (, N 10), nodular hyperplasia from hemodialy-
sis and renal transplant patients with secondary hyperparathyroidism similar animal model Dusso et al [53] found that a low
(, N  15), and diffuse hyperplasia also from hemodialysis and renal phosphorus diet may inhibit parathyroid cell prolifera-transplant patients with secondary hyperparathyroidism (, N  21).
tion by increasing the expression of the cyclin-dependentValues of PTH are the percent (mean  SE) of maximal stimulation.
Values of maximal PTH stimulation were 292  75, 371  95, and kinase inhibitor p21, whereas a high phosphate diet may
423  73 pg of d/L gDNA/h, respectively. From calcium 0.8 to 1.5 mol/L, stimulate parathyroid cell proliferation by enhancing thethe reduction of PTH was significantly greater (P  0.01) in diffuse
expression of transforming growth factor- (TGF-).hyperplasia than in adenoma.
There are genes potentially involved in uremic hyper-
parathyroidism. In uremic rats the increase in parathy-
roid cell proliferation is associated with increased c-myc
involved in the development of polyclonal parathyroid expression [38]. Acidic fibroblast growth factor autocrine
hyperplasia appear to be the same factors that stimulate system has been proposed as a mediator of calcium-
PTH secretion and synthesis: hypocalcemia, hyperphos- regulated parathyroid cell growth in a clonal cell model
[54]. In hyperplastic human parathyroid glands, prolifer-phatemia, and low serum calcitriol levels. The precise
ating cells have a low expression of PTHrP [55] andmechanism by which each of these factors stimulates
an increased expression of TGF-. [56]. Changes in theparathyroid cell proliferation is unknown.
expression of all these genes may be the consequenceIn rats on a low calcium diet with or without renal fail-
rather that the cause of parathyroid hyperplasia.ure, there is a marked increase in parathyroid cell prolif-
eration [34]. This effect is enhanced if rats have vitamin
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Fig. 4. The effect of increasing concentrations
of calcitriol on the percent of cells in the S
phase of the parathyroid cell cycle and apopto-
sis. It was assesed by flow cyitometry in normal
dog parathyroid tissue (A and B) and in hu-
man hyperplastic glands from patient with
2HPT (C and D). The cell cycle and apoptosis
were evaluated after 24 h incubation in two
different aliquots from the same tissue sample.
N 10 for A and B; N 30 (individual glands)
for C and D. Values are mean  SE, (*) P 
0.05 vs control and (#) P  0.05 vs. calcit-
riol 109 mol/L (A and B) or 108 mol/L (C
and D).
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